Zilucoplan (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zilucoplan" in English language version.

refsWebsite

Global rank English rank

5web.archive.org

1^st place

4europa.eu

68^th place

117^th place

3doi.org

2^nd place

2tga.gov.au

3,984^th place

2,622^nd place

2semanticscholar.org

11^th place

8^th place

2handle.net

102^nd place

76^th place

2nih.gov

4^th place

2fda.gov

447^th place

338^th place

1legislation.gov.au

6,658^th place

4,027^th place

1canada.ca

1,712^th place

1,063^rd place

1hpfb-dgpsa.ca

low place

1neurology.org

9,919^th place

low place

canada.ca

"Notice: Multiple additions to the Prescription Drug List (PDL) [2024-08-13]". Health Canada. 13 August 2024. Retrieved 15 August 2024.

doi.org

Howard JF, Kaminski HJ, Nowak RJ, Wolfe GI, Benatar MG, Ricardo A, et al. (April 2018). "RA101495, a subcutaneously administered peptide inhibitor of complement component 5 (C5) for the treatment of generalized myasthenia gravis (gMG): Phase 1 results and phase 2 design (S31. 006)". Neurology. 90 (15 Supplement). doi:10.1212/WNL.90.15_supplement.S31.006. S2CID 56969245. Archived from the original on 22 February 2022. Retrieved 24 June 2021.
Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, et al. (May 2021). "Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis". Expert Opinion on Investigational Drugs. 30 (5): 483–493. doi:10.1080/13543784.2021.1897567. hdl:11250/2770699. PMID 33792453. S2CID 232482753.
Ricardo A, Arata M, DeMarco S, Dhamnaskar K, Hammer R, Fridkis-Hareli M, et al. (2015). "Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria". Blood. 126 (23): 939. doi:10.1182/blood.V126.23.939.939.

europa.eu

ema.europa.eu

"Zilbrysq EPAR". European Medicines Agency. 1 December 2023. Retrieved 11 December 2023.
"Zilbrysq: Pending EC decision". European Medicines Agency. 15 September 2023. Archived from the original on 26 September 2023. Retrieved 24 September 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EU/3/22/2650: Orphan designation for the treatment of myasthenia gravis". European Medicines Agency. 15 September 2023. Archived from the original on 29 January 2023. Retrieved 24 September 2023.

ec.europa.eu

"Zilbrysq Product information". Union Register of medicinal products. 4 December 2023. Archived from the original on 11 December 2023. Retrieved 11 December 2023.

fda.gov

"Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 22 December 2023. Retrieved 27 December 2023.

accessdata.fda.gov

"Zilucoplan Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Archived from the original on 17 October 2023. Retrieved 19 October 2023.

handle.net

hdl.handle.net

Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, et al. (May 2021). "Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis". Expert Opinion on Investigational Drugs. 30 (5): 483–493. doi:10.1080/13543784.2021.1897567. hdl:11250/2770699. PMID 33792453. S2CID 232482753.
World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Regulatory Decision Summary for Zilbrysq". Drug and Health Products Portal. 11 July 2024. Retrieved 27 December 2024.

legislation.gov.au

"Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Retrieved 10 June 2024.

neurology.org

n.neurology.org

Howard JF, Kaminski HJ, Nowak RJ, Wolfe GI, Benatar MG, Ricardo A, et al. (April 2018). "RA101495, a subcutaneously administered peptide inhibitor of complement component 5 (C5) for the treatment of generalized myasthenia gravis (gMG): Phase 1 results and phase 2 design (S31. 006)". Neurology. 90 (15 Supplement). doi:10.1212/WNL.90.15_supplement.S31.006. S2CID 56969245. Archived from the original on 22 February 2022. Retrieved 24 June 2021.

nih.gov

dailymed.nlm.nih.gov

"Zilbrysq- zilucoplan injection, solution". DailyMed. 19 July 2024. Retrieved 15 September 2024.

pubmed.ncbi.nlm.nih.gov

Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, et al. (May 2021). "Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis". Expert Opinion on Investigational Drugs. 30 (5): 483–493. doi:10.1080/13543784.2021.1897567. hdl:11250/2770699. PMID 33792453. S2CID 232482753.

semanticscholar.org

api.semanticscholar.org

Howard JF, Kaminski HJ, Nowak RJ, Wolfe GI, Benatar MG, Ricardo A, et al. (April 2018). "RA101495, a subcutaneously administered peptide inhibitor of complement component 5 (C5) for the treatment of generalized myasthenia gravis (gMG): Phase 1 results and phase 2 design (S31. 006)". Neurology. 90 (15 Supplement). doi:10.1212/WNL.90.15_supplement.S31.006. S2CID 56969245. Archived from the original on 22 February 2022. Retrieved 24 June 2021.
Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, et al. (May 2021). "Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis". Expert Opinion on Investigational Drugs. 30 (5): 483–493. doi:10.1080/13543784.2021.1897567. hdl:11250/2770699. PMID 33792453. S2CID 232482753.

tga.gov.au

"Zilbrysq (zilucoplan)". Therapeutic Goods Administration (TGA). 24 September 2024. Retrieved 12 October 2024.
"Zilbrysq (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)". Therapeutic Goods Administration (TGA). 13 September 2024. Retrieved 15 September 2024.

web.archive.org

"Zilbrysq Product information". Union Register of medicinal products. 4 December 2023. Archived from the original on 11 December 2023. Retrieved 11 December 2023.
Howard JF, Kaminski HJ, Nowak RJ, Wolfe GI, Benatar MG, Ricardo A, et al. (April 2018). "RA101495, a subcutaneously administered peptide inhibitor of complement component 5 (C5) for the treatment of generalized myasthenia gravis (gMG): Phase 1 results and phase 2 design (S31. 006)". Neurology. 90 (15 Supplement). doi:10.1212/WNL.90.15_supplement.S31.006. S2CID 56969245. Archived from the original on 22 February 2022. Retrieved 24 June 2021.
"Zilbrysq: Pending EC decision". European Medicines Agency. 15 September 2023. Archived from the original on 26 September 2023. Retrieved 24 September 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Zilucoplan Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Archived from the original on 17 October 2023. Retrieved 19 October 2023.
"EU/3/22/2650: Orphan designation for the treatment of myasthenia gravis". European Medicines Agency. 15 September 2023. Archived from the original on 29 January 2023. Retrieved 24 September 2023.